Results for: Theriva Biologics

Theriva Biologics, Inc. (TOVX) stock surged over 30% after the company announced it was chosen as a finalist for Merck KGaA’s EMEA Advance Biotech Grant. This prestigious grant provides financial support and guidance to promising biotech companies. Theriva’s General Director of EU Subsidiary, Manel Cascalló, will present their innovative cancer treatment, VCN-01, at the BIO Europe 2024 conference in Stockholm, Sweden. Investors are optimistic about Theriva’s potential and the implications this grant could have for the company’s future.

Theriva Biologics Inc. (TOVX) stock is on the rise this week, driven by a series of positive developments, including the FDA’s granting of Rare Pediatric Drug Designation (RPDD) for its retinoblastoma treatment, VCN-01, and the allowance of a patent application for treating C. difficile disease. The company’s recent reverse stock split has also contributed to price volatility.

Theriva Biologics Inc. (TOVX) shares have plummeted 15% after the company announced a 1-for-25 reverse stock split, effective August 26. The move aims to ensure the company meets NYSE American listing requirements. This article explores the implications of the reverse split and provides insights into potential investment strategies.